Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program

Vir Biotechnology, Inc.

Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.
CoV Antibody Program narrowed to only sotrovimab and VIR-7832; all other antibodies revert to Vir.
Vir pays tiered royalties in low single digits on vaccine sales, low-to-mid single digits on terminated antibodies.
Amendments effective March 31, 2022 (vaccine wind-down) and February 8, 2023 (antibody scope reduction).
GSK retains 50:50 profit share on sotrovimab and VIR-7832 under original DCA terms.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vir Biotechnology, Inc. entered into Amendment No. 2 and Amendment No. 3 to the DCA with GSK (effective 2023-02-08).

Action: entry
Agreement: collaboration
Counterparty: GSK
Effective: 2023-02-08

Exact text from the filing

On February 8, 2023, the Company, and GSK entered into Amendment No. 2 and Amendment No. 3 to the DCA (collectively, the “DCA Amendments”).

View on SEC.gov

Browse all material agreements →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-035908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.